Novel immune cell therapy may be a promising strategy for combating HBV infection

NewsGuard 100/100 Score

Chronic infection with the hepatitis B virus (HBV) causes progressive liver problems, and eradication of the virus remains a formidable challenge. New research in FEBS Letters indicates that treatment that boosts the effects of immune cells called stem cell memory T cells (TSCMs) may be a promising strategy for combating HBV.

In the study, investigators identified TSCMs in patients with chronic HBV infection and analyzed their effects in a mouse model of HBV. After introducing TSCMs from patients into the mice, the immune cells differentiated into cytotoxic T cells and activated a strong response that resulted in the elimination of HBV-infected liver cells. Therefore, augmenting patients' TSCMs may help the immune system overcome the virus.

Our hepatitis model may reveal how TSCMs differentiate into cytotoxic T cells and uncover the fate of differentiated T cells. Such information could greatly advance future research on T cell-based therapies." 

Hiromi Abe-Chayama, PhD, corresponding author of Hiroshima University, Japan

Journal reference:

Abe-Chayama, H., et al. (2024) Hepatitis B virus-specific human stem cell memory T cells differentiate into cytotoxic T cells and eradicate HBV-infected hepatocytes in mice. FEBS Letters.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthroughs in germline-targeting HIV vaccine design for broad protection